ChemoMetec A/S (CHEMM.CO)
ChemoMetec A/S operates in the Medical - Devices industry of the Healthcare sector, headquartered in Allerød, CR, DK. The stock last traded at $466.20, down 1.85% on the session, giving a market capitalisation of $8.11B. Its beta of 1.38 implies it has historically moved more than the broad market.
Headquartered in Allerød, Denmark, and established in 1997, ChemoMetec A/S focuses on the design, production, and worldwide distribution of analytical instruments for cell enumeration and analysis. Their sophisticated solutions are utilized across diverse fields, including cell-based therapeutics, oncology and stem cell research, pharmaceutical development and manufacturing, along with quality assurance for animal semen and beer. The company's product offerings feature a range of NucleoCounter devices, such as the NC-3000 advanced image cytometer, the NC-250 automated cell analyzer, and the consistent NC-202 and NC-200 automated cell counters for viability assessment. Specialized counters include the NucleoCounter SP-100 for automated sperm cell analysis in animal production, the SCC-100 for measuring somatic cells in milk samples, and the YC-100 for total count and viability of yeast cells. Beyond equipment, they also supply vital consumables like cassettes and reagents, various accessories such as software and cables, and offer extensive service and validation plans.
ChemoMetec A/S is most often compared with the following Healthcare names: